Latvian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
angiotensin/vēzis
Saite tiek saglabāta starpliktuvē
Lappuse 1 no 33 rezultātiem
Use of des-aspartate-angiotensin I to treat patients exhibiting malignant growth, invasive growth, tumor, tumor metastasis or cancer
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF INVENTION
The present invention relates to the treatment of pathologies and diseases that are inflammatory in nature. The treatment is practiced by the administration of des-aspartate-angiotensin I or its derivatives to a subject in need of such a treatment. The present invention further
Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION
The present invention relates to compositions and methods for the treatment and prevention of cancer. More specifically, the present invention relates to the use of angiotensin-(1-7) or other agonists for the angiotensin-(1-7) receptor as anticancer
Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION
The present invention relates to compositions and methods for the treatment and prevention of cancer. More specifically, the present invention relates to the use of angiotensin-(1-7) or other agonists for the angiotensin-(1-7) receptor as anticancer
CDNAS encoding mouse and rat type-2 angiotensin II receptors and their expression in host cells
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
INTRODUCTION
1. Technical Field
The technical field of this invention concerns the identification and cloning of an angiotensin II type 2 receptor, a peptide hormone receptor involved in growth and differentiation, and the use of this novel receptor in the diagnosis and treatment of cardiovascular
Methods for inhibiting tumor cell proliferation
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION
This present invention relates to compositions and methods useful for the inhibition of tumor cell proliferation.
BACKGROUND OF THE INVENTION
Despite many years of promising new therapies, cancer remains a major cause of morbidity and mortality (Bailar et al., N. Engl. J. Med.
Cancer diagnosis and therapy
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD
The present invention provides a novel approach to cancer diagnosis and cancer therapy. In particular, the identification and specific targeting of cancer stem cell populations present in a tumour to eradicate or slow or prevent tumour growth and spread, including the potential for
Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
In the article by Leonardo A. Fernandez et al. entitled Renin-Angiotensin and Development of collateral Circulation After Renal Ischemia, Am.J. Physiol. 243 (Hart, Circ. Physiol. 12) H869-H875, 1982, it is reported that the infusion of angiotensin-II to aortic-ligated
Treatment of tumors
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
This application is a 371 of International Application No. PCT/AT2009/000136, filed 7 Apr. 2009, which claims priority to A566/2008, filed 9 Apr. 2008, all of which are herein incorporated by reference in their entireties.
The invention relates to the treatment of tumours.
According to information
C-Met receptor regulation by angiotensin IV (AT.sub.4) receptor ligands
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
STATEMENT REGARDING SEQUENCE LISTING
The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is
Systems for delivery and release of angiotensin-(1-7)
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
This application is the U.S. national phase of international application PCT/BR02/00156 filed in English on 05 Nov. 2002, which designated the U.S. PCT/BR02/00156 claims priority to BR Application No. PI 0105509-7 filed 05 Nov. 2001. The entire contents of these applications are incorporated herein
Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. National Stage filing of International Application Serial No. PCT/GB2003/003758 filed Aug. 21, 2003, which claims priority to GB 0219524.6 filed Aug. 21, 2002, each of which is incorporated herein by reference in its
Therapeutic uses of monoclonal antibodies to the angiotensin-II type 1 receptor
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION
The present invention relates to therapeutic uses of monoclonal antibodies to the angiotensin-II type-I receptor, in particular in the treatment of cancer and vascular smooth muscle cell proliferation.
BACKGROUND OF THE INVENTION
Angiotensin-II plays a central role in
Methods, compounds, and compositions for the treatment of angiotensin-related diseases
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION
This invention relates to novel heteroaryl non-peptidic compounds that mimic the heptapeptide angiotensin (1-7) [Ang(1-7)] and act as agonists of the Mas receptor, especially in a selective manner. The invention further relates to methods of using such compounds as therapeutic
C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
1. Field of the Invention
Embodiments of the invention disclosed herein relate generally to compositions and methods for altering hepatocyte growth factor activity or c-Met receptor activity. Certain aspects relate to the diagnosis, prevention or treatment of, as well as
Methods, compounds, and compositions for the treatment of angiotensin-related diseases
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION
This invention relates to novel heteroaryl non-peptidic compounds that mimic the heptapeptide angiotensin (1-7) [Ang(1-7)] and act as agonists of the Mas receptor, especially in a selective manner. The invention further relates to methods of using such compounds as therapeutic
Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne
- Darbojas 55 valodās
- Zāļu ārstniecības līdzekļi, kurus atbalsta zinātne
- Garšaugu atpazīšana pēc attēla
- Interaktīva GPS karte - atzīmējiet garšaugus atrašanās vietā (drīzumā)
- Lasiet zinātniskās publikācijas, kas saistītas ar jūsu meklēšanu
- Meklēt ārstniecības augus pēc to iedarbības
- Organizējiet savas intereses un sekojiet līdzi jaunumiem, klīniskajiem izmēģinājumiem un patentiem
Ierakstiet simptomu vai slimību un izlasiet par garšaugiem, kas varētu palīdzēt, ierakstiet zāli un redziet slimības un simptomus, pret kuriem tā tiek lietota.
* Visa informācija ir balstīta uz publicētiem zinātniskiem pētījumiem
